{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:19:19Z","timestamp":1791497959552,"version":"4.3.4"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40272-025-00726-1","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:47:38Z","timestamp":1761068858000},"page":"31-42","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Medulloblastoma: Current Standard of Care and Future Treatment Opportunities"],"prefix":"10.1007","volume":"28","author":[{"given":"Lisa","family":"Mayr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amedeo A.","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Gojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5736-8231","authenticated-orcid":false,"given":"Andreas","family":"Peyrl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"726_CR1","doi-asserted-by":"crossref","unstructured":"Price M, Ballard C, Benedetti J, Neff C, Cioffi G, Waite KA, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017\u20132021. Neuro Oncol. 2024;26:vi1\u201385.","DOI":"10.1093\/neuonc\/noae145"},{"key":"726_CR2","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1001\/archneurpsyc.1925.02200140055002","volume":"14","author":"P Bailey","year":"1925","unstructured":"Bailey P, Cushing H. Medulloblastoma cerebelli: a common type of midcerebellar glioma of childhood. Arch Neurol Psychiatry. 1925;14:192\u2013224.","journal-title":"Arch Neurol Psychiatry"},{"key":"726_CR3","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1148\/radiol.14140130","volume":"273","author":"M Castillo","year":"2014","unstructured":"Castillo M. History and evolution of brain tumor imaging: insights through radiology. Radiology. 2014;273:S111\u201325.","journal-title":"Radiology"},{"key":"726_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","volume":"114","author":"DN Louis","year":"2007","unstructured":"Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97\u2013109.","journal-title":"Acta Neuropathol"},{"key":"726_CR5","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/415436a","volume":"415","author":"SL Pomeroy","year":"2002","unstructured":"Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002;415:436\u201342.","journal-title":"Nature"},{"key":"726_CR6","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2016.01.015","volume":"164","author":"D Sturm","year":"2016","unstructured":"Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DTW, Capper D, et al. New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell. 2016;164:1060\u201372.","journal-title":"Cell"},{"key":"726_CR7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803\u201320.","journal-title":"Acta Neuropathol"},{"key":"726_CR8","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00401-011-0922-z","volume":"123","author":"MD Taylor","year":"2012","unstructured":"Taylor MD, Northcott PA, Korshunov A, Remke M, Cho Y-J, Clifford SC, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123:465\u201372.","journal-title":"Acta Neuropathol"},{"key":"726_CR9","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S1470-2045(17)30243-7","volume":"18","author":"EC Schwalbe","year":"2017","unstructured":"Schwalbe EC, Lindsey JC, Nakjang S, Crosier S, Smith AJ, Hicks D, et al. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncol. 2017;18:958\u201371.","journal-title":"Lancet Oncol"},{"key":"726_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00401-019-02020-0","volume":"138","author":"T Sharma","year":"2019","unstructured":"Sharma T, Schwalbe EC, Williamson D, Sill M, Hovestadt V, Mynarek M, et al. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. Acta Neuropathol. 2019;138:309\u201326.","journal-title":"Acta Neuropathol"},{"key":"726_CR11","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231\u201351.","journal-title":"Neuro Oncol"},{"key":"726_CR12","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S1470-2045(15)00581-1","volume":"17","author":"EM Thompson","year":"2016","unstructured":"Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, et al. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol. 2016;17:484\u201395.","journal-title":"Lancet Oncol"},{"key":"726_CR13","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1001\/jama.1948.72890240003006a","volume":"136","author":"HW Dargeon","year":"1948","unstructured":"Dargeon HW. Cancer in children from birth to fourteen years of age. J Am Med Assoc. 1948;136:459\u201368.","journal-title":"J Am Med Assoc"},{"key":"726_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3109\/00016925309136718","volume":"39","author":"E Paterson","year":"2010","unstructured":"Paterson E, Farr RF. Cerebellar medulloblastoma: treatment by irradiation of the whole central nervous system. Acta Radiol. 2010;39:323\u201336.","journal-title":"Acta Radiol"},{"key":"726_CR15","first-page":"51","volume":"100","author":"RD Jenkin","year":"1969","unstructured":"Jenkin RD. Medulloblastoma in childhood: radiation therapy. Can Med Assoc J. 1969;100:51\u20133.","journal-title":"Can Med Assoc J"},{"key":"726_CR16","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1148\/93.6.1351","volume":"93","author":"CH Chang","year":"1969","unstructured":"Chang CH, Housepian EM, Herbert C. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology. 1969;93:1351\u20139.","journal-title":"Radiology"},{"key":"726_CR17","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1200\/JCO.2000.18.16.3004","volume":"18","author":"PR Thomas","year":"2000","unstructured":"Thomas PR, Deutsch M, Kepner JL, Boyett JM, Krischer J, et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol. 2000;18:3004\u201311.","journal-title":"J Clin Oncol"},{"key":"726_CR18","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3171\/jns.1990.72.4.0572","volume":"72","author":"AE Evans","year":"1990","unstructured":"Evans AE, Jenkin RD, Sposto R, Ortega JA, Wilson CB, Wara W, et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg. 1990;72:572\u201382.","journal-title":"J Neurosurg"},{"key":"726_CR19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/0277-5379(90)90017-N","volume":"26","author":"DM Tait","year":"1990","unstructured":"Tait DM, Thornton-Jones H, Bloom HJ, Lemerle J, Morris-Jones P. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer. 1990;26:464\u20139.","journal-title":"Eur J Cancer"},{"key":"726_CR20","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1200\/JCO.1999.17.3.832","volume":"17","author":"PM Zeltzer","year":"1999","unstructured":"Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children\u2019s Cancer Group 921 randomized phase III study. J Clin Oncol. 1999;17:832\u201345.","journal-title":"J Clin Oncol"},{"key":"726_CR21","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3171\/jns.1994.81.5.0690","volume":"81","author":"RJ Packer","year":"1994","unstructured":"Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson HS, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg. 1994;81:690\u20138.","journal-title":"J Neurosurg"},{"key":"726_CR22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0360-3016(99)00369-7","volume":"46","author":"R-D Kortmann","year":"2000","unstructured":"Kortmann R-D, K\u00fchl J, Timmermann B, Mittler U, Urban C, Budach V, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT \u201991. Int J Radiat Oncol Biol Phys. 2000;46:269\u201379.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"726_CR23","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1200\/JCO.2006.06.4980","volume":"24","author":"RJ Packer","year":"2006","unstructured":"Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24:4202\u20138.","journal-title":"J Clin Oncol"},{"key":"726_CR24","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1200\/JCO.1989.7.11.1660","volume":"7","author":"RK Mulhern","year":"1989","unstructured":"Mulhern RK, Horowitz ME, Kovnar EH, Langston J, Sanford RA, Kun LE. Neurodevelopmental status of infants and young children treated for brain tumors with preirradiation chemotherapy. J Clin Oncol. 1989;7:1660\u20136.","journal-title":"J Clin Oncol"},{"key":"726_CR25","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/(SICI)1096-911X(199812)31:6<506::AID-MPO7>3.0.CO;2-X","volume":"31","author":"D Jenkin","year":"1998","unstructured":"Jenkin D, Danjoux C, Greenberg M. Subsequent quality of life for children irradiated for a brain tumor before age four years. Med Pediatr Oncol. 1998;31:506\u201311.","journal-title":"Med Pediatr Oncol"},{"key":"726_CR26","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/(SICI)1096-911X(199705)28:5<348::AID-MPO4>3.0.CO;2-H","volume":"28","author":"AE Kiltie","year":"1997","unstructured":"Kiltie AE, Lashford LS, Gattamaneni HR. Survival and late effects in medulloblastoma patients treated with craniospinal irradiation under three years old. Med Pediatr Oncol. 1997;28:348\u201354.","journal-title":"Med Pediatr Oncol"},{"key":"726_CR27","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/BF00301666","volume":"11","author":"E Hoppe-Hirsch","year":"1995","unstructured":"Hoppe-Hirsch E, Brunet L, Laroussinie F, Cinalli G, Pierre-Kahn A, R\u00e9nier D, et al. Intellectual outcome in children with malignant tumors of the posterior fossa: influence of the field of irradiation and quality of surgery. Childs Nerv Syst. 1995;11:340\u20135.","journal-title":"Childs Nerv Syst"},{"key":"726_CR28","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1200\/JCO.2001.19.8.2302","volume":"19","author":"SL Palmer","year":"2001","unstructured":"Palmer SL, Goloubeva O, Reddick WE, Glass JO, Gajjar A, Kun L, et al. Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis. J Clin Oncol. 2001;19:2302\u20138.","journal-title":"J Clin Oncol"},{"key":"726_CR29","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1056\/NEJMoa042176","volume":"352","author":"S Rutkowski","year":"2005","unstructured":"Rutkowski S, Bode U, Deinlein F, Ottensmeier H, Warmuth-Metz M, Soerensen N, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med. 2005;352:978\u201386.","journal-title":"N Engl J Med"},{"key":"726_CR30","doi-asserted-by":"publisher","unstructured":"Mazewski C, Leary SES, Kang G, Li BK, Kellie S, Hayes L, et al. Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: a report from the Children\u2019s Oncology Group. Neuro Oncol. 2025:noaf132. https:\/\/doi.org\/10.1093\/neuonc\/noaf132.","DOI":"10.1093\/neuonc\/noaf132"},{"key":"726_CR31","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1001\/jamaoncol.2021.2224","volume":"7","author":"SES Leary","year":"2021","unstructured":"Leary SES, Packer RJ, Li Y, Billups CA, Smith KS, Jaju A, et al. Efficacy of carboplatin and isotretinoin in children with high-risk medulloblastoma: a randomized clinical trial from the Children\u2019s Oncology Group. JAMA Oncol. 2021;7:1313\u201321.","journal-title":"JAMA Oncol"},{"key":"726_CR32","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1200\/JCO.2011.39.8719","volume":"30","author":"B Lannering","year":"2012","unstructured":"Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, Navajas A, et al. Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol. 2012;30:3187\u201393.","journal-title":"J Clin Oncol"},{"key":"726_CR33","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.ijrobp.2015.04.023","volume":"92","author":"H C\u00e2mara-Costa","year":"2015","unstructured":"C\u00e2mara-Costa H, Resch A, Kieffer V, Lalande C, Poggi G, Kennedy C, et al. Neuropsychological outcome of children treated for standard risk medulloblastoma in the PNET4 European randomized controlled trial of hyperfractionated versus standard radiation therapy and maintenance chemotherapy. Int J Radiat Oncol Biol Phys. 2015;92:978\u201385.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"726_CR34","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1200\/JCO.2016.67.2428","volume":"34","author":"AO von Bueren","year":"2016","unstructured":"von Bueren AO, Kortmann R-D, von Hoff K, Friedrich C, Mynarek M, M\u00fcller K, et al. Treatment of children and adolescents with metastatic medulloblastoma and prognostic relevance of clinical and biologic parameters. J Clin Oncol. 2016;34:4151\u201360.","journal-title":"J Clin Oncol"},{"key":"726_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/neuonc\/noae189","volume":"27","author":"M Massimino","year":"2024","unstructured":"Massimino M, Barretta F, Dossena C, Minasi S, Buttarelli FR, Biassoni V, et al. Long-term outcome of the Milano-hyperfractionated accelerated radiotherapy strategy for high-risk medulloblastoma, including the impact of molecular subtype. Neuro Oncol. 2024;27:209\u201318.","journal-title":"Neuro Oncol"},{"key":"726_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00184-5","volume":"24","author":"S Yan","year":"2023","unstructured":"Yan S, Ngoma TA, Ngwa W, Bortfeld TR. Global democratisation of proton radiotherapy. Lancet Oncol. 2023;24:e245\u201354.","journal-title":"Lancet Oncol"},{"key":"726_CR37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/ncponc0090","volume":"1","author":"TI Yock","year":"2004","unstructured":"Yock TI, Tarbell NJ. Technology insight: proton beam radiotherapy for treatment in pediatric brain tumors. Nat Clin Pract Oncol. 2004;1:97\u2013103.","journal-title":"Nat Clin Pract Oncol"},{"key":"726_CR38","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1200\/JCO.19.01706","volume":"38","author":"LS Kahalley","year":"2020","unstructured":"Kahalley LS, Peterson R, Ris MD, Janzen L, Okcu MF, Grosshans DR, et al. Superior intellectual outcomes after proton radiotherapy compared with photon radiotherapy for pediatric medulloblastoma. J Clin Oncol. 2020;38:454\u201361.","journal-title":"J Clin Oncol"},{"key":"726_CR39","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1158\/1078-0432.CCR-23-0348","volume":"29","author":"KJ Cohen","year":"2023","unstructured":"Cohen KJ, Munjapara V, Aguilera D, Castellino RC, Stapleton SL, Landi D, et al. A pilot study omitting radiation in the treatment of children with newly diagnosed Wnt-activated medulloblastoma. Clin Cancer Res. 2023;29:5031\u20137.","journal-title":"Clin Cancer Res"},{"key":"726_CR40","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1200\/JCO.19.00845","volume":"38","author":"L Lafay-Cousin","year":"2020","unstructured":"Lafay-Cousin L, Bouffet E, Strother D, Rudneva V, Hawkins C, Eberhart C, et al. Phase II study of nonmetastatic desmoplastic medulloblastoma in children younger than 4 years of age: a report of the Children\u2019s Oncology Group (ACNS1221). J Clin Oncol. 2020;38:223\u201331.","journal-title":"J Clin Oncol"},{"key":"726_CR41","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1200\/JCO.20.02730","volume":"39","author":"JM Michalski","year":"2021","unstructured":"Michalski JM, Janss AJ, Vezina LG, Smith KS, Billups CA, Burger PC, et al. Children\u2019s oncology group phase III trial of reduced-dose and reduced-volume radiotherapy with chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2021;39:2685\u201397.","journal-title":"J Clin Oncol"},{"key":"726_CR42","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/S1470-2045(13)70449-2","volume":"14","author":"V Ramaswamy","year":"2013","unstructured":"Ramaswamy V, Remke M, Bouffet E, Faria CC, Perreault S, Cho Y-J, et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol. 2013;14:1200\u20137.","journal-title":"Lancet Oncol"},{"key":"726_CR43","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.ejca.2011.03.004","volume":"47","author":"B Pizer","year":"2011","unstructured":"Pizer B, Donachie PHJ, Robinson K, Taylor RE, Michalski A, Punt J, et al. Treatment of recurrent central nervous system primitive neuroectodermal tumours in children and adolescents: results of a Children\u2019s Cancer and Leukaemia Group study. Eur J Cancer. 2011;47:1389\u201397.","journal-title":"Eur J Cancer"},{"key":"726_CR44","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s11060-016-2202-1","volume":"129","author":"M Sabel","year":"2016","unstructured":"Sabel M, Fleischhack G, Tippelt S, Gustafsson G, Doz F, Kortmann R, et al. Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. J Neurooncol. 2016;129:515\u201324.","journal-title":"J Neurooncol"},{"key":"726_CR45","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S2352-4642(20)30246-7","volume":"4","author":"RM Hill","year":"2020","unstructured":"Hill RM, Richardson S, Schwalbe EC, Hicks D, Lindsey JC, Crosier S, et al. Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study. Lancet Child Adolesc Health. 2020;4:865\u201374.","journal-title":"Lancet Child Adolesc Health"},{"key":"726_CR46","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1200\/JCO.20.01359","volume":"39","author":"R Kumar","year":"2021","unstructured":"Kumar R, Smith KS, Deng M, Terhune C, Robinson GW, Orr BA, et al. Clinical outcomes and patient-matched molecular composition of relapsed medulloblastoma. J Clin Oncol. 2021;39:807\u201321.","journal-title":"J Clin Oncol"},{"key":"726_CR47","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/cancers13010053","volume":"13","author":"S Huybrechts","year":"2020","unstructured":"Huybrechts S, Teuff GL, Tauzi\u00e8de-Espariat A, Rossoni C, Chivet A, Indersie \u00c9, et al. Prognostic clinical and biologic features for overall survival after relapse in childhood medulloblastoma. Cancers. 2020;13:53.","journal-title":"Cancers"},{"key":"726_CR48","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3390\/cancers14010126","volume":"14","author":"RM Hill","year":"2021","unstructured":"Hill RM, Plasschaert SLA, Timmermann B, Dufour C, Aquilina K, Avula S, et al. Relapsed medulloblastoma in pre-irradiated patients: current practice for diagnostics and treatment. Cancers. 2021;14:126.","journal-title":"Cancers"},{"key":"726_CR49","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10238-025-01648-5","volume":"25","author":"Z Pan","year":"2025","unstructured":"Pan Z, Bao J, Wei S. Advancing medulloblastoma therapy: strategies and survival insights. Clin Exp Med. 2025;25:119.","journal-title":"Clin Exp Med"},{"key":"726_CR50","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3390\/cancers14030471","volume":"14","author":"C Gaab","year":"2022","unstructured":"Gaab C, Adolph JE, Tippelt S, Mikasch R, Obrecht D, Mynarek M, et al. Local and systemic therapy of recurrent medulloblastomas in children and adolescents: results of the P-HIT-REZ 2005 study. Cancers. 2022;14:471.","journal-title":"Cancers"},{"key":"726_CR51","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/cncr.22761","volume":"110","author":"V Ridola","year":"2007","unstructured":"Ridola V, Grill J, Doz F, Gentet J, Frappaz D, Raquin M, et al. High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy. Cancer. 2007;110:156\u201363.","journal-title":"Cancer"},{"key":"726_CR52","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/pbc.22378","volume":"54","author":"A Gajjar","year":"2010","unstructured":"Gajjar A, Pizer B. Role of high-dose chemotherapy for recurrent medulloblastoma and other CNS primitive neuroectodermal tumors. Pediatr Blood Cancer. 2010;54:649\u201351.","journal-title":"Pediatr Blood Cancer"},{"key":"726_CR53","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1200\/JCO.1998.16.1.222","volume":"16","author":"IJ Dunkel","year":"1998","unstructured":"Dunkel IJ, Boyett JM, Yates A, Rosenblum M, Garvin JH, Bostrom BC, et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma: Children\u2019s Cancer Group. J Clin Oncol. 1998;16:222\u20138.","journal-title":"J Clin Oncol"},{"key":"726_CR54","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1002\/cncr.28907","volume":"120","author":"C Wetmore","year":"2014","unstructured":"Wetmore C, Herington D, Lin T, Onar-Thomas A, Gajjar A, Merchant TE. Reirradiation of recurrent medulloblastoma: does clinical benefit outweigh risk for toxicity? Cancer. 2014;120:3731\u20137.","journal-title":"Cancer"},{"key":"726_CR55","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11060-019-03272-2","volume":"145","author":"DS Tsang","year":"2019","unstructured":"Tsang DS, Sarhan N, Ramaswamy V, Nobre L, Yee R, Taylor MD, et al. Re-irradiation for children with recurrent medulloblastoma in Toronto, Canada: a 20-year experience. J Neurooncol. 2019;145:107\u201314.","journal-title":"J Neurooncol"},{"key":"726_CR56","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1200\/JCO.21.02968","volume":"41","author":"C Erker","year":"2023","unstructured":"Erker C, Mynarek M, Bailey S, Mazewski CM, Baroni L, Massimino M, et al. Outcomes of infants and young children with relapsed medulloblastoma after initial craniospinal irradiation-sparing approaches: an international cohort study. J Clin Oncol. 2023;41:1921\u201332.","journal-title":"J Clin Oncol"},{"key":"726_CR57","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf092","author":"C Erker","year":"2025","unstructured":"Erker C, Mynarek M, Simbozel M, Craig BT, Harrod VL, Cappellano AM, et al. Salvage therapies for first relapse of SHH medulloblastoma in early childhood. Neuro Oncol. 2025. https:\/\/doi.org\/10.1093\/neuonc\/noaf092.","journal-title":"Neuro Oncol"},{"key":"726_CR58","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1093\/neuonc\/not097","volume":"15","author":"J Grill","year":"2013","unstructured":"Grill J, Geoerger B, Gesner L, Perek D, Leblond P, Ca\u00f1ete A, et al. Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study. Neuro Oncol. 2013;15:1236\u201343.","journal-title":"Neuro Oncol"},{"key":"726_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29031","volume":"68","author":"AS Levy","year":"2021","unstructured":"Levy AS, Krailo M, Chi S, Villaluna D, Springer L, Williams-Hughes C, et al. Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: report of a COG randomized phase II screening trial. Pediatr Blood Cancer. 2021;68:e29031.","journal-title":"Pediatr Blood Cancer"},{"key":"726_CR60","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1001\/jamaoncol.2023.4437","volume":"9","author":"A Peyrl","year":"2023","unstructured":"Peyrl A, Chocholous M, Sabel M, Lassaletta A, Sterba J, Leblond P, et al. Sustained survival benefit in recurrent medulloblastoma by a metronomic antiangiogenic regimen. JAMA Oncol. 2023;9:1688\u201395.","journal-title":"JAMA Oncol"},{"key":"726_CR61","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1093\/neuonc\/nou006","volume":"16","author":"JE Schreiber","year":"2014","unstructured":"Schreiber JE, Schreiber JE, Gurney JG, Gurney JG, Palmer SL, Palmer SL, et al. Examination of risk factors for intellectual and academic outcomes following treatment for pediatric medulloblastoma. Neuro Oncol. 2014;16:1129\u201336.","journal-title":"Neuro Oncol"},{"key":"726_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31246","volume":"71","author":"J Felker","year":"2024","unstructured":"Felker J, Bjornard K, Close A, Chavez J, Chow EJ, Meacham LR, et al. Fertility preservation in pediatric central nervous system tumors: a report from the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2024;71:e31246.","journal-title":"Pediatr Blood Cancer"},{"key":"726_CR63","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/neuonc\/noae119","volume":"27","author":"C Papini","year":"2025","unstructured":"Papini C, Mirzaei S, Xing M, Tonning Olsson I, Salloum R, et al. Neurocognitive outcomes and functional independence in adult survivors of childhood medulloblastoma diagnosed over 3 decades. Neuro Oncol. 2025;27:254\u201366.","journal-title":"Neuro Oncol"},{"key":"726_CR64","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1007\/s00381-015-2829-9","volume":"31","author":"A Lassaletta","year":"2015","unstructured":"Lassaletta A, Bouffet E, Mabbott D, Kulkarni AV. Functional and neuropsychological late outcomes in posterior fossa tumors in children. Childs Nerv Syst. 2015;31:1877\u201390.","journal-title":"Childs Nerv Syst"},{"key":"726_CR65","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1001\/jamaoncol.2024.6812","volume":"11","author":"A DeVine","year":"2025","unstructured":"DeVine A, Landier W, Hudson MM, Constine LS, Bhatia S, et al. The children\u2019s oncology group long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers: a review. JAMA Oncol. 2025;11:544\u201353.","journal-title":"JAMA Oncol"},{"key":"726_CR66","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1200\/JCO.2012.47.4775","volume":"31","author":"SL Palmer","year":"2013","unstructured":"Palmer SL, Armstrong C, Onar-Thomas A, Wu S, Wallace D, Bonner MJ, et al. Processing speed, attention, and working memory after treatment for medulloblastoma: an international, prospective, and longitudinal study. J Clin Oncol. 2013;31:3494\u2013500.","journal-title":"J Clin Oncol"},{"key":"726_CR67","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/neuonc\/noae092","volume":"26","author":"M Mynarek","year":"2024","unstructured":"Mynarek M, Rossius A, Guiard A, Ottensmeier H, von Hoff K, Obrecht-Sturm D, et al. Risk factors for domain-specific neurocognitive outcome in pediatric survivors of a brain tumor in the posterior fossa: results of the HIT 2000 trial. Neuro Oncol. 2024;26:2113\u201324.","journal-title":"Neuro Oncol"},{"key":"726_CR68","doi-asserted-by":"publisher","first-page":"8588","DOI":"10.1200\/JCO.2004.00.5355","volume":"23","author":"KRG Knight","year":"2005","unstructured":"Knight KRG, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005;23:8588\u201396.","journal-title":"J Clin Oncol"},{"key":"726_CR69","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1093\/neuonc\/nox135","volume":"19","author":"JE Schreiber","year":"2017","unstructured":"Schreiber JE, Palmer SL, Conklin HM, Mabbott DJ, Swain MA, Bonner MJ, et al. Posterior fossa syndrome and long-term neuropsychological outcomes among children treated for medulloblastoma on a multi-institutional, prospective study. Neuro Oncol. 2017;19:1673\u201382.","journal-title":"Neuro Oncol"},{"key":"726_CR70","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ccell.2020.03.012","volume":"37","author":"E Kilgour","year":"2020","unstructured":"Kilgour E, Rothwell DG, Brady G, Dive C. Liquid biopsy-based biomarkers of treatment response and resistance. Cancer Cell. 2020;37:485\u201395.","journal-title":"Cancer Cell"},{"key":"726_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103100","volume":"62","author":"A Alba-Bernal","year":"2020","unstructured":"Alba-Bernal A, Lavado-Valenzuela R, Dom\u00ednguez-Recio ME, Jim\u00e9nez-Rodriguez B, Queipo-Ortu\u00f1o MI, Alba E, et al. Challenges and achievements of liquid biopsy technologies employed in early breast cancer. EBioMedicine. 2020;62:103100.","journal-title":"EBioMedicine"},{"key":"726_CR72","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.ccell.2021.09.012","volume":"39","author":"APY Liu","year":"2021","unstructured":"Liu APY, Smith KS, Kumar R, Paul L, Bihannic L, Lin T, et al. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell. 2021;39:1519-30.e4.","journal-title":"Cancer Cell"},{"key":"726_CR73","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.3390\/cancers15092525","volume":"15","author":"N Stepien","year":"2023","unstructured":"Stepien N, Senfter D, Furtner J, Haberler C, Dorfer C, Czech T, et al. Proof-of-concept for liquid biopsy disease monitoring of MYC-amplified group 3 medulloblastoma by droplet digital PCR. Cancers. 2023;15:2525.","journal-title":"Cancers"},{"key":"726_CR74","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdae126","volume":"6","author":"EE Crotty","year":"2024","unstructured":"Crotty EE, Paulson VA, Ronsley R, Vitanza NA, Lee A, Hauptman J, et al. Cerebrospinal fluid liquid biopsy by low-pass whole genome sequencing for clinical disease monitoring in pediatric embryonal tumors. Neuro-Oncol Adv. 2024;6:vdae126.","journal-title":"Neuro-Oncol Adv"},{"key":"726_CR75","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.devcel.2005.12.013","volume":"10","author":"J Sv\u00e4rd","year":"2006","unstructured":"Sv\u00e4rd J, Heby-Henricson K, Henricson KH, Persson-Lek M, Rozell B, Lauth M, et al. Genetic elimination of suppressor of fused reveals an essential repressor function in the mammalian Hedgehog signaling pathway. Dev Cell. 2006;10:187\u201397.","journal-title":"Dev Cell"},{"key":"726_CR76","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1056\/NEJMoa0902903","volume":"361","author":"CM Rudin","year":"2009","unstructured":"Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361:1173\u20138.","journal-title":"N Engl J Med"},{"key":"726_CR77","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1200\/JCO.2014.60.1591","volume":"33","author":"GW Robinson","year":"2015","unstructured":"Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I, et al. Vismodegib exerts targeted efficacy against recurrent Sonic Hedgehog-subgroup medulloblastoma: results from phase II Pediatric Brain Tumor Consortium studies PBTC-025B and PBTC-032. J Clin Oncol. 2015;33:2646\u201354.","journal-title":"J Clin Oncol"},{"key":"726_CR78","doi-asserted-by":"publisher","first-page":"6305","DOI":"10.1158\/1078-0432.CCR-13-1425","volume":"19","author":"A Gajjar","year":"2013","unstructured":"Gajjar A, Stewart CF, Ellison DW, Kaste S, Kun LE, Packer RJ, et al. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res. 2013;19:6305\u201312.","journal-title":"Clin Cancer Res"},{"key":"726_CR79","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1093\/neuonc\/noab087","volume":"23","author":"D Frappaz","year":"2021","unstructured":"Frappaz D, Barritault M, Montan\u00e9 L, Laigle-Donadey F, Chinot O, Rhun EL, et al. MEVITEM: a phase I\/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent\/refractory medulloblastoma with Sonic Hedgehog pathway activation. Neuro Oncol. 2021;23:1949\u201360.","journal-title":"Neuro Oncol"},{"key":"726_CR80","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s12032-025-02734-0","volume":"42","author":"C Xu","year":"2025","unstructured":"Xu C, Wang B, Xu T, Lv Y, Pan X, Zhao X, et al. EZH2 inhibitor and vismodegib synergistically inhibit the growth and metastasis of medulloblastoma. Med Oncol. 2025;42:186.","journal-title":"Med Oncol"},{"key":"726_CR81","doi-asserted-by":"publisher","DOI":"10.1002\/open.202500119","volume":"14","author":"IA Tsakoumagkos","year":"2025","unstructured":"Tsakoumagkos IA, Pasquer QTL, Guillod C, Rossion C, Bagka M, Torche S, et al. Evaluation of benzo[cd]indol-2(1h)-ones as downstream Hedgehog pathway inhibitors. ChemistryOpen. 2025;14:e202500119.","journal-title":"ChemistryOpen"},{"key":"726_CR82","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ccell.2019.07.009","volume":"36","author":"L Zhang","year":"2019","unstructured":"Zhang L, He X, Liu X, Zhang F, Huang LF, Potter AS, et al. Single-cell transcriptomics in medulloblastoma reveals tumor-initiating progenitors and oncogenic cascades during tumorigenesis and relapse. Cancer Cell. 2019;36:302-18.e7.","journal-title":"Cancer Cell"},{"key":"726_CR83","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/s41467-024-54861-3","volume":"16","author":"Y Li","year":"2025","unstructured":"Li Y, Lim C, Dismuke T, Malawsky DS, Oasa S, Bruce ZC, et al. Suppressing recurrence in Sonic Hedgehog subgroup medulloblastoma using the OLIG2 inhibitor CT-179. Nat Commun. 2025;16:1091.","journal-title":"Nat Commun"},{"key":"726_CR84","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1093\/neuonc\/noae104","volume":"26","author":"L Zhou","year":"2024","unstructured":"Zhou L, Bree N, Boutin L, Ryu J, Moussaud S, Liu M, et al. High-throughput neural stem cell-based drug screening identifies S6K1 inhibition as a selective vulnerability in sonic hedgehog-medulloblastoma. Neuro Oncol. 2024;26:1685\u201399.","journal-title":"Neuro Oncol"},{"key":"726_CR85","doi-asserted-by":"crossref","unstructured":"Sobral LM, Walker FM, Madhavan K, Janko E, Donthula S, Danis E, et al. Targeting processive transcription for Myc-driven circuitry in medulloblastoma. Neuro Oncol. 2025;noaf121.","DOI":"10.1093\/neuonc\/noaf121"},{"key":"726_CR86","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41420-025-02470-4","volume":"11","author":"P Gou","year":"2025","unstructured":"Gou P, Fang C, Xu M, Zhang D, Wu X, Zhang L, et al. The dual HDAC\/PI3K inhibitor CUDC-907 inhibits the growth and proliferation of MYC-driven group 3 medulloblastoma. Cell Death Discov. 2025;11:172.","journal-title":"Cell Death Discov."},{"key":"726_CR87","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41388-024-03232-9","volume":"44","author":"J Yu","year":"2025","unstructured":"Yu J, Han J, Yu M, Rui H, Sun A, Li H. EZH2 inhibition sensitizes MYC-high medulloblastoma cancers to PARP inhibition by regulating NUPR1-mediated DNA repair. Oncogene. 2025;44:391\u2013405.","journal-title":"Oncogene"},{"issue":"8","key":"726_CR88","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1097\/CAD.0000000000001728","volume":"36","author":"EM Thompson","year":"2025","unstructured":"Thompson EM, Cheng L, Spasojevic I. Enhanced plasma and brain concentrations and medulloblastoma cytotoxicity of asciminib and nilotinib by P-glycoprotein inhibition with tariquidar. Anticancer Drugs. 2025;36(8):622\u20138.","journal-title":"Anticancer Drugs"},{"key":"726_CR89","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adi1617","volume":"15","author":"M Khang","year":"2023","unstructured":"Khang M, Lee JH, Lee T, Suh H-W, Lee S, Cavaliere A, et al. Intrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastoma. Sci Transl Med. 2023;15:eadi1617.","journal-title":"Sci Transl Med"},{"key":"726_CR90","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3390\/pharmaceutics17060736","volume":"17","author":"A Foti","year":"2025","unstructured":"Foti A, Allia F, Briglia M, Malaguarnera R, Tamburrini G, Cecconi F, et al. Medulloblastoma: molecular targets and innovative theranostic approaches. Pharmaceutics. 2025;17:736.","journal-title":"Pharmaceutics"},{"key":"726_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121138","volume":"278","author":"V Kumar","year":"2021","unstructured":"Kumar V, Wang Q, Sethi B, Lin F, Kumar V, Coulter DW, et al. Polymeric nanomedicine for overcoming resistance mechanisms in hedgehog and Myc-amplified medulloblastoma. Biomaterials. 2021;278:121138.","journal-title":"Biomaterials"},{"key":"726_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113268","volume":"215","author":"J Wen","year":"2021","unstructured":"Wen J, Hadden MK. Medulloblastoma drugs in development: current leads, trials and drawbacks. Eur J Med Chem. 2021;215:113268.","journal-title":"Eur J Med Chem"},{"key":"726_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16122249","volume":"16","author":"H Slika","year":"2024","unstructured":"Slika H, Shahani A, Wahi R, Miller J, Groves M, Tyler B. Overcoming treatment resistance in medulloblastoma: underlying mechanisms and potential strategies. Cancers (Basel). 2024;16:2249.","journal-title":"Cancers (Basel)"},{"key":"726_CR94","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1158\/1078-0432.CCR-23-2959","volume":"30","author":"SA Gatz","year":"2023","unstructured":"Gatz SA, Harttrampf AC, Brard C, Bautista F, Andr\u00e9 N, Abbou S, et al. Phase I\/II study of the WEE1 inhibitor adavosertib (AZD1775) in combination with carboplatin in children with advanced malignancies: arm C of the AcS\u00e9-ESMART trial. Clin Cancer Res. 2023;30:741\u201353.","journal-title":"Clin Cancer Res"},{"key":"726_CR95","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1002\/cncr.34786","volume":"129","author":"KA Cole","year":"2023","unstructured":"Cole KA, Ijaz H, Surrey LF, Santi M, Liu X, Minard CG, et al. Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma. Cancer. 2023;129:2245\u201355.","journal-title":"Cancer"},{"key":"726_CR96","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/ijc.34569","volume":"153","author":"D Eslin","year":"2023","unstructured":"Eslin D, Zage PE, Bergendahl G, Lewis E, Roberts W, Kraveka J, et al. A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma. Int J Cancer. 2023;153:1026\u201334.","journal-title":"Int J Cancer"},{"key":"726_CR97","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","volume":"25","author":"Z Ying","year":"2019","unstructured":"Ying Z, Huang XF, Xiang X, Liu Y, Kang X, Song Y, et al. A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019;25:947\u201353.","journal-title":"Nat Med"},{"key":"726_CR98","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1158\/1078-0432.CCR-23-1880","volume":"30","author":"R Ciccone","year":"2024","unstructured":"Ciccone R, Quintarelli C, Camera A, Pezzella M, Caruso S, Manni S, et al. GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma. Clin Cancer Res. 2024;30:2545\u201357.","journal-title":"Clin Cancer Res"},{"key":"726_CR99","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","volume":"40","author":"JD Wolchok","year":"2022","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022;40:127\u201337.","journal-title":"J Clin Oncol"},{"key":"726_CR100","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1158\/1078-0432.CCR-23-0411","volume":"29","author":"A Das","year":"2023","unstructured":"Das A, Tabori U, Nahum LCS, Collins NB, Deyell R, Dvir R, et al. Efficacy of nivolumab in pediatric cancers with high mutation burden and mismatch-repair deficiency. Clin Cancer Res. 2023;29:4770\u201383.","journal-title":"Clin Cancer Res"},{"key":"726_CR101","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/neuonc\/noad031","volume":"25","author":"IJ Dunkel","year":"2023","unstructured":"Dunkel IJ, Doz F, Foreman NK, Hargrave D, Lassaletta A, Andr\u00e9 N, et al. Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: safety, efficacy, biomarker, and pharmacokinetics\u2014CheckMate 908. Neuro Oncol. 2023;25:1530\u201345.","journal-title":"Neuro Oncol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00726-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-025-00726-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00726-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:02:37Z","timestamp":1770048157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-025-00726-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["726"],"URL":"https:\/\/doi.org\/10.1007\/s40272-025-00726-1","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"15 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lisa Mayr, Amedeo A. Azizi, Johannes Gojo, and Andreas Peyrl have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data used in the preparation of this article are available from the cited sources referenced in the paper.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"AP and LM conceptualized the content, drafted the initial manuscript, and critically reviewed the manuscript. AA and JG critically reviewed the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}